ArticlePloS one2011
Epigenetic activation of SOX11 in lymphoid neoplasms by histone modifications.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- The utility of mRNA analysis in defining SOX11 expression levels in mantle cell lymphoma and reactive lymph nodes.Haematologica · 2015Trial
- Vitamin a modulates neurogenesis-associated pathways and cholinergic signaling in Alzheimer's disease: potential role of reactive astrocytes via NGN2/SOX-11 and SIRT-1.Scientific reports · 2026Article
- Article
- Systematic Investigation of the Multifaceted Role ofCancers · 2022Article
- Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma.Leukemia · 2022Article
- Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation.Nature communications · 2021Article
- Clinicopathological features and prognostic value of SOX11 in childhood acute lymphoblastic leukemia.Scientific reports · 2020Article
- Sox11 promotes head and neck cancer progression via the regulation of SDCCAG8.Journal of experimental & clinical cancer research : CR · 2019Article
- Article
- SOX11: friend or foe in tumor prevention and carcinogenesis?Therapeutic advances in medical oncology · 2019Review
- Potential added value of a RT-qPCR method of SOX 11 expression, in the context of a multidisciplinary diagnostic assessment of B cell malignancies.Experimental hematology & oncology · 2018Article
- Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage.Cancer cell · 2016Article
- Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.Blood · 2016Article
- Aberrant SOX11 promoter methylation is associated with poor prognosis in gastric cancer.Cellular oncology (Dordrecht, Netherlands) · 2015Article
- DNA methylation and histone modifications regulate SOX11 expression in lymphoid and solid cancer cells.BMC cancer · 2015Article
- Article
- The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.Leukemia & lymphoma · 2014Article
- Promoter methylation status of the tumor suppressor gene SOX11 is associated with cell growth and invasion in nasopharyngeal carcinoma.Cancer cell international · 2013Article
- SOXC transcription factors in mantle cell lymphoma: the role of promoter methylation in SOX11 expression.Scientific reports · 2013Article
- t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth.Blood · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 11 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies have shown aberrant expression of SOX11 in various types of aggressive B-cell neoplasms. To elucidate the molecular mechanisms leading to such deregulation, we performed a comprehensive SOX11 gene expression and epigenetic study in stem cells, normal hematopoietic cells and different lymphoid neoplasms. We observed that SOX11 expression is associated with unmethylated DNA and presence of activating histone marks (H3K9/14Ac and H3K4me3) in embryonic stem cells and some aggressive B-cell neoplasms. In contrast, adult stem cells, normal hematopoietic cells and other lymphoid neoplasms do not express SOX11. Such repression was associated with silencing histone marks H3K9me2 and H3K27me3. The SOX11 promoter of non-malignant cells was consistently unmethylated whereas lymphoid neoplasms with silenced SOX11 tended to acquire DNA hypermethylation. SOX11 silencing in cell lines was reversed by the histone deacetylase inhibitor SAHA but not by the DNA methyltransferase inhibitor AZA. These data indicate that, although DNA hypermethylation of SOX11 is frequent in lymphoid neoplasms, it seems to be functionally inert, as SOX11 is already silenced in the hematopoietic system. In contrast, the pathogenic role of SOX11 is associated with its de novo expression in some aggressive lymphoid malignancies, which is mediated by a shift from inactivating to activating histone modifications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.